These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8078843)

  • 41. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis.
    Hirsh J
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):20-5. PubMed ID: 9399406
    [No Abstract]   [Full Text] [Related]  

  • 42. [Rationalization of risk factors for venous thromboembolism in medical inpatients. A prospective study].
    Pottier P; Planchon B; Truchaud F; Pistorius MA; Furic I; Grolleau JY
    J Mal Vasc; 2000 Oct; 25(4):241-9. PubMed ID: 11060418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of deep venous thrombosis.
    Mayo Clin Proc; 1986 Jun; 61(6):507-8. PubMed ID: 3713259
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery.
    Hauch O; Khattar SC; Jørgensen LN
    Semin Thromb Hemost; 1991; 17 Suppl 3():280-3. PubMed ID: 1661436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of superficial thrombophlebitis].
    Raake W; Binder M
    Hamostaseologie; 2002 Dec; 22(4):149-53. PubMed ID: 12540973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The use of fraxiparin in orthopedic trauma patients to prevent and treat pulmonary embolism and deep venous thrombosis of the extremities].
    Mironov SP; Burmakova GM; Fedotova TM
    Ter Arkh; 1993; 65(10):82-3. PubMed ID: 8296243
    [No Abstract]   [Full Text] [Related]  

  • 47. [Meta-analysis on randomized trials comparing the results of low-molecular weight heparins to those of fractioned heparins in the prevention of deep venous thrombosis].
    Daures JP; Schved JF; Momas I; Gril JC; Azoulay P; Gremy F
    Rev Epidemiol Sante Publique; 1989; 37(4):363-9. PubMed ID: 2558404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
    Kalfarentzos F; Stavropoulou F; Yarmenitis S; Kehagias I; Karamesini M; Dimitrakopoulos A; Maniati A
    Obes Surg; 2001 Dec; 11(6):670-6. PubMed ID: 11775562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Fraxiparin as a component of lymphotropic polychemotherapy of locally spread valvular cancer in patients with chronic venous insufficiency].
    Tkachuk TIe
    Lik Sprava; 2002; (5-6):93-6. PubMed ID: 12442536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
    Forette B; Wolmark Y
    Presse Med; 1995 Mar; 24(12):567-71. PubMed ID: 7770402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The future of low molecular weight heparins in the curative treatment of deep venous thrombosis].
    St-Louis J; St-Louis JM
    Union Med Can; 1994 Mar; 123(3):147-51. PubMed ID: 8184510
    [No Abstract]   [Full Text] [Related]  

  • 52. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis.
    Hull RD; Raskob GE; Hirsh J; Sackett DL
    JAMA; 1984 Jul; 252(2):235-9. PubMed ID: 6427492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Studies raise possibility of home therapy for acute deep-vein thrombosis.
    Am J Health Syst Pharm; 1996 May; 53(9):975-6. PubMed ID: 8744450
    [No Abstract]   [Full Text] [Related]  

  • 54. [Continuous heparin therapy in deep venous thrombosis and its monitoring with the Howel and thrombin times. Prospective study].
    Lozano Sánchez F; Almazán Enríquez A; Ramos Boyero M; del Villar Galán JL; Gómez Alonso A
    Angiologia; 1981; 33(5):272-82. PubMed ID: 7325396
    [No Abstract]   [Full Text] [Related]  

  • 55. Home treatment of deep vein thrombosis: a two-years experience of a single institution.
    Grau E; Real E; Pastor E; Viciano V; Aguiló J
    Haematologica; 1998 May; 83(5):438-41. PubMed ID: 9658729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The new heparins].
    Samama M; Babinet-Berthier A
    J Mal Vasc; 1992; 17(2):91-106. PubMed ID: 1319447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the relative efficacy and safety of low-molecular-weight heparin and unfractionated heparin for the treatment of venous thrombosis.
    Hirsh J
    Semin Thromb Hemost; 1996; 22 Suppl 2():7-12; discussion 29-30. PubMed ID: 8946613
    [No Abstract]   [Full Text] [Related]  

  • 58. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study.
    Shafiq N; Malhotra S; Pandhi P; Sharma N; Bhalla A; Grover A
    Pharmacology; 2006; 78(3):136-43. PubMed ID: 17057417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.